Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

Justin F. Gainor; Jeffrey Gary Schneider; Martin Gutierrez; James Michael Orcutt; Gene Grant Finley; Gregory Alan Otterson; Igor I. Rybkin; Pavan S. Reddy; Leora Horn; Julie R. Brahmer; Bruno R. Bastos; Mark M. Awad; Matthew David Hellmann; Suresh S. Ramalingam; Neal E. Ready; David R. Spigel; Ravi S. Kasinathan; Cécile Dorange; Hossein Borghaei

doi:10.1200/JCO.2020.38.15_SUPPL.9560

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

Justin F. Gainor, Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Rybkin, Pavan S. Reddy, Leora Horn, Julie R. Brahmer, Bruno R. Bastos, Mark M. Awad, Matthew David Hellmann, Suresh S. Ramalingam, Neal E. Ready, David R. Spigel, Ravi S. Kasinathan, Cécile Dorange, Hossein Borghaei

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9560
State	Published - 2020
Event	2020 ASCO Annual Meeting - Duration: Jan 1 2020 → …

Conference

Conference	2020 ASCO Annual Meeting
Period	1/1/20 → …

Disciplines

Oncology
Pathology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1200/JCO.2020.38.15_SUPPL.9560License: Unspecified

Cite this

Gainor, J. F., Schneider, J. G., Gutierrez, M., Orcutt, J. M., Finley, G. G., Otterson, G. A., Rybkin, I. I., Reddy, P. S., Horn, L., Brahmer, J. R., Bastos, B. R., Awad, M. M., Hellmann, M. D., Ramalingam, S. S., Ready, N. E., Spigel, D. R., Kasinathan, R. S., Dorange, C., & Borghaei, H. (2020). Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.. 2020 ASCO Annual Meeting. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9560

Gainor, JF, Schneider, JG, Gutierrez, M, Orcutt, JM, Finley, GG, Otterson, GA, Rybkin, II, Reddy, PS, Horn, L, Brahmer, JR, Bastos, BR, Awad, MM, Hellmann, MD, Ramalingam, SS, Ready, NE, Spigel, DR, Kasinathan, RS, Dorange, C & Borghaei, H 2020, 'Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.', 2020 ASCO Annual Meeting, 1/1/20. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9560

@conference{2370d830fdec4370b9167aa65b41def6,

title = "Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.",

author = "Gainor, \{Justin F.\} and Schneider, \{Jeffrey Gary\} and Martin Gutierrez and Orcutt, \{James Michael\} and Finley, \{Gene Grant\} and Otterson, \{Gregory Alan\} and Rybkin, \{Igor I.\} and Reddy, \{Pavan S.\} and Leora Horn and Brahmer, \{Julie R.\} and Bastos, \{Bruno R.\} and Awad, \{Mark M.\} and Hellmann, \{Matthew David\} and Ramalingam, \{Suresh S.\} and Ready, \{Neal E.\} and Spigel, \{David R.\} and Kasinathan, \{Ravi S.\} and C{\'e}cile Dorange and Hossein Borghaei",

note = "9560 Background: In Part 1 of the phase II CheckMate 568 study (NCT02659059), NIVO + IPI was active and tolerable in patients (pts) with advanced NSCLC. The addition of chemo to dual immune checkpoint inhibitor therapy may further improve initial disease control.; 2020 ASCO Annual Meeting ; Conference date: 01-01-2020",

year = "2020",

doi = "10.1200/JCO.2020.38.15\_SUPPL.9560",

language = "American English",

}

TY - CONF

T1 - Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

AU - Gainor, Justin F.

AU - Schneider, Jeffrey Gary

AU - Gutierrez, Martin

AU - Orcutt, James Michael

AU - Finley, Gene Grant

AU - Otterson, Gregory Alan

AU - Rybkin, Igor I.

AU - Reddy, Pavan S.

AU - Horn, Leora

AU - Brahmer, Julie R.

AU - Bastos, Bruno R.

AU - Awad, Mark M.

AU - Hellmann, Matthew David

AU - Ramalingam, Suresh S.

AU - Ready, Neal E.

AU - Spigel, David R.

AU - Kasinathan, Ravi S.

AU - Dorange, Cécile

AU - Borghaei, Hossein

N1 - 9560 Background: In Part 1 of the phase II CheckMate 568 study (NCT02659059), NIVO + IPI was active and tolerable in patients (pts) with advanced NSCLC. The addition of chemo to dual immune checkpoint inhibitor therapy may further improve initial disease control.

PY - 2020

Y1 - 2020

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9560

U2 - 10.1200/JCO.2020.38.15_SUPPL.9560

DO - 10.1200/JCO.2020.38.15_SUPPL.9560

M3 - Presentation

T2 - 2020 ASCO Annual Meeting

Y2 - 1 January 2020

ER -

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

Conference

Disciplines

Access to Document

Other files and links

Cite this